Conflict of interest
S. Altrichter, S. Wöhrl, F. Horak, M. Idzko, G. Jordakieva, E. Untersmayr, Z. Szepfalusi, P. Zieglmayer, E. Jensen-Jarolim, U. Wiedermann, A. Rosenkranz and W. Hötzenecker declare no conflicts of interest relevant to the content of this article. Outside the present work, S. Altrichter has performed studies/was a consultant for/was a speaker for Allakos, AstraZeneca, CSL Behring, Moxie, and Novartis. S. Wöhrl has been a consultant and/or speaker for AbbVie, ALK, Allergopharma, Bencard, DrFalk, HAL, MEDA, Novartis, Lilly, Pelpharma, Sanofi-Aventis, Siemens Healthineers, Stallergenes, and ThermoFisher Scientific. F. Horak has been a consultant for LETI, has conducted studies with ALK and Bencard Allergy, and has been a speaker for HAL and Allergopharma. M. Idzko has been a consultant and/or speaker for AstraZeneca, Bayer, Berlin-Chemie, Boehringer-Ingelheim, Chiesi, CSL-Behring, GSK, Menarini, MSD, Novartis, Roche, Sanofi, and Thermofisher. G. Jordakieva was a consultant for Bencard Allergie GmbH. Z. Szepfalusi was a speaker or served on advisory boards for Milupa/Nutricia, Novartis, and Medis. P. Zieglmayer has received lecture fees from Alk Abello, Allergopharma, Allergy Therapeutics, HAL, Leti, Meda, Merck, Novartis, Stallergenes, and Thermo Fisher Scientific, as well as scientific fellowships and teaching grants from Alk-Abelló, Allergopharma, Allergy Therapeutics, Biomay, Calistoga, GSK, HAL, Marinomed, MSD, Ono, Oxagen, RespiVert, Stallergenes, and VentirX. She is an advisory board member for Alk Abello, Bencard, Meda, Merck, Novartis, Sigmapharm and Stallergenes. E. Jensen-Jarolim is a shareholder in Biomedical Int. R+D GmbH and has conducted studies with Bencard Allergie, Germany and Allergy Therapeutics Ltd, UK. She has taught for Bencard, ATL, Meda, Novartis, Sanofi, Santen, Allergopharma, and Roxall. U. Wiedermann is PI on clinical trials at the Medical University sponsored by Novartis, GSK, and Pfizer. None of the trials involve COVID-19 vaccines. He receives no personal honorarium and is a member of the National Immunization Advisory Group (NIG). W. Hötzenecker has conducted studies/has been a consultant/speaker for Novartis, Eli Lilly, Bencard, ALK, Leo Pharma, Kyowa Kirin, Takeda, Sanofi-Aventis, and AbbVie.